Semaglutide 2mg: Reading the Evidence Before You Reach That Dose

How semaglutide's dosing ladder was built, and where 2mg sits in it

The titration schedule for Wegovy was designed in response to the treatment's most common side effects: nausea, vomiting and digestive discomfort that typically arrive early and settle over a few weeks. Starting low and climbing slowly gives the body time to adapt. The licensed UK steps are 0.25mg for the first four weeks, then 0.5mg, 1.0mg, 1.7mg and finally 2.4mg as the standard maintenance dose, with each step held for roughly a month before moving on.

So 2mg doesn't appear as a named rung on that ladder. It emerges in two contexts: some phase-2 trials for semaglutide tested doses of 0.2mg, 0.4mg, 0.6mg, 1.0mg and 2.0mg weekly, which is where the figure entered the published literature. It also appears in questions about the 2mg per week dose range or in comparisons with the titration steps either side of it. If you have seen 2mg cited and wondered whether your dose is on track, the short answer is that dose decisions sit with your prescriber, not with dose charts you find online.

The semaglutide overview covers the full mechanism and licensed uses in the UK, including the important distinction between Wegovy (weight management) and Ozempic (type 2 diabetes), two branded medicines using the same molecule but authorised for different conditions.

What the STEP 1 trial found, and what it means at the doses leading up to 2.4mg

The landmark evidence for semaglutide in weight management comes from the STEP programme. STEP 1, published in the New England Journal of Medicine, ran for 68 weeks and enrolled adults with obesity or overweight alongside a weight-related condition. Participants reaching the 2.4mg maintenance dose alongside lifestyle support lost an average of around 15% of body weight, compared with just under 3% in the placebo group.

Critically, most of that weight reduction was recorded after participants had spent time at the intermediate doses, the 0.5mg, 1.0mg and 1.7mg phases are not just tolerability steps; they are the period during which appetite suppression builds gradually. A dose around 2mg weekly, where it appeared in earlier trial arms, showed meaningful but generally lower average loss than 2.4mg, which is why the licenced maintenance dose was set where it was.

NICE's appraisal of Wegovy references this evidence base in recommending semaglutide for eligible adults, you can read the full recommendation at NICE TA875. The appraisal notes that treatment should be continued only if 5% or more weight loss is achieved after six months at the maintenance dose, and that use should be reviewed within a specialist-supported framework.

For context on how these results compare with the 1mg semaglutide dose range used in some diabetes contexts, the licensed weight-management doses start above that threshold.

Side effects at this stage of treatment: what patients typically report

Moving through the 1.7mg step toward 2.4mg (the portion of the titration that runs through what would be the 2mg territory) is often where GI side effects resurface briefly. Nausea is most common; loose stools, constipation, reflux and fatigue are also reported. The NHS notes on the semaglutide medicines page that these effects are generally mild to moderate and tend to settle within days to a couple of weeks after a dose change.

One thing our prescribers hear regularly: people are sometimes nervous about the next step up precisely because a previous increase was uncomfortable. That feeling is valid. Slowing the titration is a clinical decision, and it is one a prescriber can make, which is exactly why dose changes are not something to manage from a dosing chart alone.

If you experience severe, persistent stomach pain that radiates toward the back, get medical help promptly. The MHRA highlighted acute pancreatitis as an infrequent but serious risk associated with GLP-1 medicines in its January 2026 Drug Safety Update, and any suspected side effect can be reported at the Yellow Card scheme. Other reasons to contact a clinician quickly include signs of dehydration from persistent vomiting or diarrhoea, or any allergic reaction.

Separately, women using oral contraceptives during tirzepatide treatment (and to a lesser extent during semaglutide treatment) should discuss contraception with their prescriber, as gastric slowing can affect pill absorption. The relevant guidance sits on the Wegovy treatment page.

Getting to this dose: the private route via a regulated UK pharmacy

On the NHS, Wegovy is available through specialist weight management services under NICE TA875, but waiting lists in many areas remain long. A private prescription from a GPhC-registered online pharmacy is the alternative for people who meet the clinical criteria but either don't qualify for NHS access yet or prefer not to wait.

At nume, the process is straightforward: a free consultation, same-day clinical review by a GPhC-registered Independent Prescriber, and (if clinically suitable) dispatch the same day for free next-working-day delivery by DPD. One transparent price covers the consultation, prescription, treatment and aftercare. No subscription, no automatic renewals. If you are ordering around a bank holiday or a Friday (worth bearing in mind if timing matters to you) the 12pm cut-off for same-day dispatch applies on working days only, and next-day delivery follows from the dispatch date.

If you are already on treatment and want to understand what the 2mg Wegovy dose context means for your plan, that page covers the specifics in more detail. For anyone considering starting, how to get Wegovy through a regulated UK pharmacy sets out exactly what the process involves. You can also review the full range of licensed weight-loss treatments we work with before deciding.

Ready to find out whether semaglutide treatment is clinically suitable for you? Check your eligibility with a free consultation, reviewed the same day by a real prescriber.